Mechanisms of drug induced QT interval prolongation

Current Drug Safety

Volumn 5, Issue 1, 2010, Pages 44-53

  Ponte, Marcelo Luis ^a   Keller, Guillermo Alberto ^b   Di GirolamO , Guillermo ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b FAVALORO UNIVERSITY   (Argentina)

Author keywords

Congenital long QT syndrome; HERG channel; IKr current; Physiopathology; QT interval prolongation; Torsades de pointes

Indexed keywords

1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; AMIODARONE; AMITRIPTYLINE; AMPHOTERICIN B; ASTEMIZOLE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; DESIPRAMINE; DIURETIC AGENT; FLECAINIDE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; INSULIN; MEXILETINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PIMOZIDE; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNQ1; QUINIDINE; RISPERIDONE; SERTINDOLE; SERTRALINE; TAMOXIFEN; TERFENADINE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ACTION POTENTIAL; AMYLOIDOSIS; BRADYCARDIA; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM DISEASE; DIABETES MELLITUS; ELECTROLYTE DISTURBANCE; GENE MUTATION; GENETIC POLYMORPHISM; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE CELL; HUMAN; HYPOKALEMIA; HYPOTHERMIA; HYPOTHYROIDISM; LONG QT SYNDROME; OBESITY; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; REPOLARIZATION; REVIEW; T WAVE; TORSADE DES POINTES;

ANIMALS; CELL MEMBRANE; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; PROTEIN TRANSPORT; RISK FACTORS; TORSADES DE POINTES;

EID: 77950855126     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488610789869247     Document Type: Review

References (55)

1. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: Recent advances. Curr Opin Cardiol 2007; 22: 3943.
2. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf 2001; 24: 323-351
3. Roden DM. Drug-Induced Prolongation of the QT Interval. N Engl J Med 2004; 350: 1013-1022
4. Fenichel RR. Drug-Induced Torsades de Pointes and implications for drug development. J Cardiovascular Electrophysiol 2004; 15: 475-495
5. Arizona CERT. Drugs with a risk of torsades de pointes, Available from: http://www.qtdrugs.org/medical-pros/drug-lists/bycategory.cfm [Accessed April 30, 2008].
6. Tartini R, Kappenberger L, Steinbrunn W, Meyer UA. Dangerous interaction between amiodarone and quinidine. Lancet 1982; 1: 1327-1329
7. Woosley RL. Cardiac actions of antihistamines. Ann Rev Pharmacol Toxicol 1996; 36: 233-252
8. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001; 21: 1468-1472
9. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001; 104: 569-580
10. Chern EC. Congenital and acquired long QT syndrome. Current concepts and management. Cardiol Rev 2004; 12: 222-234
11. Anderson ME, Al Khatib SM, Roden DM et al. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 2002; 144: 769-781
12. Committee for Proprietary Medicinal Products. Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products 1997.
13. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920; (7): 353-370
14. Fridericia LS. The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease. Acta Medica Scandinavica 1920; (53): 469-486
15. Morissette P, Hreiche R, Turgeon J. Drug-induced long QT syndrome and torsade de pointes. Can J Cardiol 2005; 21: 857-864
16. Antzelevitch C, Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol 2002; 17: 43-51. (Pubitemid 34073163)
17. Prosser JM, Mills A, Rhim ES, et al. Torsade de pointes caused by polypharmacy and substance abuse in a patient with human immunodeficiency virus. Int J Emerg Med 2008; 1(3): 217-220
18. Sanguinetti MC, Jiang C, Curran ME, Keating M.T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81: 299-307.
19. Gintant GA. Two components of delayed rectifier current in canine atrium and ventricle. Does Iks play a role in the reverse rate dependence of class III agents? Circ Res 1996; 78: 26-37.
20. Li GR, Feng J, Yue L, et al. Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ Res 1996; 78: 689-696 (Pubitemid 26106881)
21. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the QT interval, and sudden death. Am Heart J 1957; 54: 59-68.
22. Romano C, Gemme G, Pongiglione R. Rare cardiac arrythmias of the pediatric age. II. Syncopal attacks due to paroxysmal ventricular fibrillation (Presentation oflst Case in Italian Pediatric Literature). Clin Pediatr (Bologna) 1963; 45: 656-683
23. Ward OC. A new familial cardiac syndrome in children. J Ir Med Assoc 1964; 54: 103-106
24. Modell SM, Lehmann MH. The long QT syndrome family of cardiac ion channelopathies: a huge review. Genet Med 2006; 8: 143-155
25. Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital Iong-QT syndrome: findings from the international LQTS registry. Circulation 1998; 97: 2237-2244
26. Chan AS, Isbister GK, Kirkpatrick CM, et al. Assessing risk of a prolonged QT interval-a survey of emergency physicians. Int J Emerg Med 2008; 1(1): 35-41.
27. Paran Y, Mashav N, Henis O, et al. Drug-induced torsades de pointes in patients aged 80 years or more. Anadolu Kardiyol Derg 2008; 8(4): 260-265
28. Kääb S, Pfeufer A, Hinterseer M, et al. Long QT syndrome. Why does sex matter? Z Kardiol 2004; 93: 641-645
29. Splawski I. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000; 102: 1178-1185
30. Selzer A, Wray HW. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964; 30: 17-26.
31. Roden DM, Balser JR, George AL Jr, Anderson ME. Cardiac ion channels. Annu Rev Physiol 2002; 64: 431-475
32. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000; 47: 219-233
33. De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of torsades de pointes with nonantiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 2001; 57: 185-209.
34. Fenichel RR. Development of drugs that alter ventricular repolarization. Am J Ther 2002; 9: 127-139
35. Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in drosophila and mammals. Proc Natl Acad Sci USA 1994; 91: 3438-3442
36. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995; 269: 92-95
37. Zünkler BJ. Human ether-a-go-go-related (HERG) gene and ATPsensitive potassium channels as targets for adverse drug effects. Pharmacol Therapeut 2006; 112: 12-37.
38. Shoeb F, Malykhina AP, Akbarali HI. Cloning and functional characterization of the smooth muscle ether-a-go-go-related gene K+channel. Potential role of a conserved amino acid substitution in the S4 region. J Biol Chem 2003; 278: 2503-2514
39. Bianchi L, Wible B, Arcangeli A, et al. HERG encodes a K+current highly conserved in tumors of different histogenesis: A selective advantage for cancer cells? Cancer Res 1998; 58: 815-822
40. Roche B, Kijtawornrat A, Hamlin R, et al. Relationship between prolongation of QTc and prolongation of the peak of T (Tp) to the end of T(Te). J Pharmacol Toxicol Methods 2005; 52: 178-181
41. Hii JT, Wyse DG, Gillis AM, et al. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992; 86(5): 1376-1382
42. Antzelevitch C. Drug-induced spatial dispersion of repolarization. Cardiol J 2008; 15(2): 100-121
43. Keivanidou A, Arnaoutoglou C, Krommydas A, et al. Moxifloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. Cardiol J 2009; 16(2): 172-174
44. Stockley. Interacciones Farmacológicas. 2da Ed. Pharma Ed 2007. Barcelona.
45. Alistair JJ, Wood MD. Drug-induced prolongation of the QT interval. Neng J Med 2004; 350(10): 1013-1022
46. Sicouri S, Antzelevithc C. Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf 2008; 7(2): 181-194
47. Badshah A, Mirza B, Janjua M, et al. Amiodarone-induced torsade de pointes in a patient with wolff-Parkinson-white syndrome. Hellenic J Cardiol 2009; 50(3): 224-226
48. Raschi E, Poluzzi E, Zuliani C, et al. Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period. Br J Clin Pharmacol 2009; 67(1): 88-98.
49. Sakaguchi T, Itoh H, Ding WG, et al. Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-gorelated gene (HERG) current and causes syncope in a patient with the HERG mutation. J Pharmacol Sci 2008; 108(4): 462-471
50. Shojaie M, Eshraghian A. Primary hypothyroidism presenting with Torsades de pointes type tachycardia: a case report. Cases J 2008; 1(1): 298.
51. Roden DM. Taking the ïdiö out of ïdiosyncratic̈: Predicting torsades de pointes. PACE 1998; 21: 1029-1034
52. Webster R, Leishman D, Walker D, et al. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Dev 2002; 5: 116-126
53. Anyukhovsky EP, Sosunov EA, Rosen MR. Regional differences in electrophysiological properties of epicardium, midmyocardium, and endocardium. In vitro and in vivo correlations. Circulation 1996; 94: 1981-1988
54. Ye L, Feng J, Li GR, Nattel S. Transient outward and delayed rectifier currents in canine atrium: properties and role of isolation methods. Am J Physiol 1996; 272: H1292-301.
55. Sims C, Reisenweber S, Viswanathan PC, et al. Sex, age, and regional differences in L-type calcium current are important determinants of arrhythmia phenotype in rabbit hearts with druginduced long QT type 2. Circ Res 2008; 102(9): e86-100.